Cost-effectiveness analysis of ribociclib versus abemaciclib as first-line treatments for postmenopausal women with HR+/HER2– advanced breast cancer: a Medicare perspective
Ribociclib improves health outcomes with a modest impact on costs and is likely to be more cost-effective than abemaciclib for postmenopausal women requiring 1 L treatment of HR+/HER2- aBC from a Medicare perspective.
Authors
- Thomas E. Delea (ORCID: https://orcid.org/0000-0001-5493-1925)
- Sarah Sammons (ORCID: https://orcid.org/0000-0003-2589-9422)
- Purnima Pathak (ORCID: https://orcid.org/0000-0002-6225-9128)
- Vijayakrishna K. Gadi (ORCID: https://orcid.org/0000-0002-5427-7465)
- Paolo Tarantino (ORCID: https://orcid.org/0000-0001-8686-0228)
- Daniel Stellato
- Gary Sopher
Institutions
- Novartis (Switzerland) (CH)
- University of Illinois Chicago (US)
- Prevea Health (US)
- Translational Research in Oncology (FR)
- Dana-Farber Cancer Institute (US)
- Novartis (United States) (US)
Publication Details
- Journal
- Journal of Medical Economics
- Published
- 2025-12-05
- DOI
- https://doi.org/10.1080/13696998.2025.2594951
- Primary Topic
- Advanced Breast Cancer Therapies
- Type
- article
- Field-Weighted Citation Impact
- 0.00